- Home
- HAFN vs ICUI Comparison
HAFN vs ICUI Comparison
Compare HAFN & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAFN
- ICUI
- Stock Information
- Founded
- HAFN 2012
- ICUI 1984
- Country
- HAFN Bermuda
- ICUI United States
- Employees
- HAFN N/A
- ICUI N/A
- Industry
- HAFN
- ICUI Medical/Dental Instruments
- Sector
- HAFN
- ICUI Health Care
- Exchange
- HAFN Nasdaq
- ICUI Nasdaq
- Market Cap
- HAFN 2.8B
- ICUI 3.8B
- IPO Year
- HAFN N/A
- ICUI 1992
- Fundamental
- Price
- HAFN $6.10
- ICUI $161.08
- Analyst Decision
- HAFN Strong Buy
- ICUI Buy
- Analyst Count
- HAFN 2
- ICUI 4
- Target Price
- HAFN $8.25
- ICUI $199.67
- AVG Volume (30 Days)
- HAFN 2.4M
- ICUI 200.3K
- Earning Date
- HAFN 02-27-2025
- ICUI 02-25-2025
- Dividend Yield
- HAFN 24.87%
- ICUI N/A
- EPS Growth
- HAFN N/A
- ICUI N/A
- EPS
- HAFN 1.69
- ICUI N/A
- Revenue
- HAFN $3,039,225,000.00
- ICUI $2,340,097,000.00
- Revenue This Year
- HAFN N/A
- ICUI $4.38
- Revenue Next Year
- HAFN N/A
- ICUI $0.34
- P/E Ratio
- HAFN $3.60
- ICUI N/A
- Revenue Growth
- HAFN 15.24
- ICUI 4.04
- 52 Week Low
- HAFN $4.99
- ICUI $86.80
- 52 Week High
- HAFN $8.99
- ICUI $196.26
- Technical
- Relative Strength Index (RSI)
- HAFN N/A
- ICUI 51.79
- Support Level
- HAFN N/A
- ICUI $151.92
- Resistance Level
- HAFN N/A
- ICUI $167.49
- Average True Range (ATR)
- HAFN 0.00
- ICUI 4.52
- MACD
- HAFN 0.00
- ICUI 0.73
- Stochastic Oscillator
- HAFN 0.00
- ICUI 61.01
About HAFN Hafnia Limited Common Shares
Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk.
About ICUI ICU Medical Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.